UTRECHT, THE NETHERLANDS, JANUARY 12th 2017 – U-PACT B.V., the molecular diagnostics company that develops technology to provide comprehensive tools for accurate assessment of bleeding risk, has received the MIT R&D collaborative project grant from the Economic Board Utrecht.
The application entitled ‘PACT, a platelet activation test that predicts bleeding risk’ was rated as more innovative compared to other applications with respect to its product development, and judged much better than average regarding its economic value. In collaboration with U-Protein Express B.V., U-PACT B.V. will use this grant to develop and validate novel reagents for its platelet function test PACT.
For more information on the PACT, please contact Dr. Suzanne Korporaal, C.O.O. at J.A.Korporaal@U-PACT.com.
For more information on U-PACT B.V., please contact Dr. Martin Hessing, C.E.O. at M.Hessing@U-PACT.com.